apricus biosciences  apri apri drug delivery system patient friendly drugs san diego by apricus bio dear shareholders over the past two quarters following the disappointing fispemifene clinical trial results we have sharpened our focus on increasing value through the fostering and expansion of our vitaros® commercial partnerships preparing the vitaros nda resubmission and improving the company’s financial position strategic priorities vitaros® alprostadil continue implementation of the us regulatory approval strategy to address the safety and manufacturing issues raised by the fda in the original vitaros nda submission in november the fda provided clarity on the requirements needed to address the deficiencies in the  complete response letter to include suggested additional analysis of existing clinical and nonclinical data the fda feedback did not indicate that new clinical studies would be required for resubmission but the fda did determine that vitaros is now considered a drugdevice combination the company intends to meet with the office of product quality to confirm the necessary device engineering and compliance requirements for the nda resubmission and then resubmit the vitaros nda in the second half of  an fda approval decision is expected after a six month review period continue to support the company’s exus partners’ efforts to build a global vitaros brand and increase revenue by supporting new commercial launches by the company’s partners and assisting the company’s partners in obtaining additional regulatory approvals in their respective territories continue the company’s efforts to license vitaros in available countries throughout asia to include japan china and india and continue to generate the required data to support delivery device improvements and related regulatory submissions with a priority to support the us nda resubmission of the refrigerated version of vitaros and to deliver a commercially viable refrigerated product in canada rayva™ alprostadil explore orphan drug designation in the us and eu and explore global or regional partnerships prior to initiating the phase b study corporatefinancial reduce operating expenses by approximately  in  and  in  as compared to  operating expenses work with nasdaq to try and regain compliance with the minimum  million market value of listed securities requirement as required for continued listing on the nasdaq capital market under nasdaq listing rule b and grow vitaros revenue seek nondilutive capital and utilize lower cost of capital financial instruments to fund operations with the goal of achieving profitability in  apricus’ development priority is now focused on vitaros both to accelerate commercialization outside of the us and to attempt to bring this novel erectile dysfunction therapy to patients in the us next year with the goal of achieving profitability in  as always thank you for your continued support and interest in apricus biosciences warm regards richard w pascoe search live with vitality ceo messageupdated   click picture to view pipeline  click picture to view nsdq  apri     news releases may   apricus biosciences provides corporate update and first quarter  financial results may   apricus biosciences announces the initiation of vitaros drugdevice human factors study presentations may   apricus biosciences corporate presentation pipeline  apricus biosciences search going the distance with apricus home  pipeline print this page pipeline apricus pipeline chart phase  phase  phase  approved marketed vitaros™ erectile dysfunctionpending nda resubmission  us rayva™ raynaud’s phenomenon vitaros™ it is estimated that worldwide  million men suffer with erectile dysfunction factors contributing to the appearance of the disease or its severity include medical history tobacco use and age erectile dysfunction is also found in men with cardiovascular disease  click to read more rayva™ raynaud’s phenomenon rp is fairly common with a reported prevalence up to  with a disproportionately higher number of women affected triggers for an raynaud’s phenomenon attack include cold temperatures caffeine smoking or emotional stress attacks are the result of reduced blood flow to areas including fingers toes nose and ears  click to read more  press releases  investors  apricus biosciences searchhomeinvestor relations press releases press releases keyword search              datetitle  apricus biosciences provides corporate update and first quarter  financial resultsvitaros us nda resubmission remains on track for third quarter  vitaros drugdevice human factor studies underway operations funded through the third quarter of  conference call  webcast today may   at  pm et san diego may   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today reported financial results for the first quarter of  and provided a corporat  apricus biosciences announces the initiation of vitaros drugdevice human factors studyvitaros us nda resubmission on track for third quarter  san diego may   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today reported that the vitaros drugdevice combination human factor testing study required by the food and drug administration fda is underway “in november of  the fda designated vitaros as a drugdevice combination and required apricus to provide a  apricus biosciences announces corporate update and first quarter  financial results conference callsan diego may   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today announced that apricus’ first quarter  financial results will be released on thursday may   at  pm eastern time  company management will host a conference call on thursday may   at  pm eastern time to discuss the financial results and other recent corporate highlights to participa  apricus biosciences regains compliance with nasdaq continued listing requirementssan diego may   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today announced that on may   apricus was notified by the nasdaq stock market llc “nasdaq” that apricus has evidenced full compliance with all criteria for continued listing on the nasdaq capital market including the minimum stockholders’ equity requirement nasdaq’s determination follows apricus’ previously an  apricus biosciences announces pricing of  million public offeringsan diego april   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today announced the pricing of an underwritten public offering of an aggregate of  units with each unit consisting of one share of apricus common stock and one warrant to purchase  of a share of common stock at a public offering price of  per unit  the shares of common stock and warrants are immediate  apricus biosciences provides corporate update fourth quarter and full year  financial resultssale of exus vitaros assets and rights to ferring pharmaceuticals strengthens financial position vitaros us nda resubmission on track for third quarter  conference call  webcast today monday march   at  pm et san diego march   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today reported financial results for the fourth quarter and full year of  and p  apricus biosciences announces corporate update fourth quarter and full year  financial results conference callsan diego march   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today announced that the companys fourth quarter and full year  financial results will be released on monday march   at  pm eastern time  company management will host a conference call on monday march   at  pm eastern time to discuss the financial results and other recent corporate highl  apricus biosciences announces sale of exus vitaros assets and rights to ferring pharmaceuticalsapricus expects to receive approximately  million from ferring apricus to focus on vitaros us nda resubmission and pipeline assets postclosing san diego march   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today announced that it completed the sale to ferring international center sa “ferring” of apricus’ exus assets and rights related to vitaros® apricus’ ondeman  apricus biosciences receives positive nasdaq listing determinationsan diego feb   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today announced that on february   the company was notified that the nasdaq hearings panel the “panel” has granted the company’s request for continued listing on nasdaq pursuant to an extension through may   by which date the company must evidence full compliance with all applicable criteria for continued   apricus biosciences to present at the th annual bio ceo  investor conferencesan diego feb   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today announced that richard pascoe chief executive officer will present at the th annual bio ceo  investor conference on tuesday february   at  am eastern time  the conference will be held at the waldorf astoria new york ny  mr pascoe will provide an update on vitaros® the companys topical t  apricus biosciences announces approval of vitaros® for the treatment of erectile dysfunction in mexicoferring plans to launch in mexico and argentina during the second quarter  san diego jan   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today announced that mexico has granted apricus’ commercialization partner ferring pharmaceuticals market approval for vitaros® an ondemand topical cream indicated for the treatment of patients with erectile dysfunction this is the twen  apricus biosciences promotes mary naggs to vice president general counselsan diego jan   globe newswire  apricus biosciences inc nasdaqapri a biopharmaceutical company advancing innovative medicines in urology and rheumatology today announced that mary naggs has been promoted to vice president general counsel effective january    ms naggs will report directly to richard pascoe the company’s chief executive officer and serve as a member of the company’s executive team ms naggs advances from the position of associate general couns  nsdq  apri    data provided by nasdaqminimum  minutes delayedinvestor relationsinvestor homestock informationnews  eventspress releasesinvestor calendarpresentationsfinancialsfundamentalscorporate governanceshareholder servicestoolkit             investor contactfor further information please contactirapricusbiocom t     institutional  retail investors matthew beck the trout group llcmbecktroutgroupcom t    el camino real suite  san diego ca  t     management  apricus biosciences search home  about apricus  management print this page management our experienced leadership team is strategically aligned to provide significant value to each of our core business initiatives richard pascoe chief executive officer richard w pascoe has been a director and served as our chief executive officer since march  and has served as the company’s secretary since february  mr pascoe joined the company following the merger of somaxon pharmaceuticals inc with pernix therapeutics holdings inc mr pascoe was the chief executive officer of somaxon from august  until joining the company and was responsible for the fda approval of somaxon’s lead drug silenor® prior to somaxon mr pascoe was with ariad pharmaceuticals inc a specialty pharmaceutical company where he was most recently senior vice president and chief operating officer prior to joining ariad in  mr pascoe held a series of senior management roles at king pharmaceuticals inc acquired by pfizer inc including senior vice president positions in both marketing and sales as well as vice president positions in both international sales and marketing and hospital sales prior to king mr pascoe was in the commercial groups at medco research inc acquired by king cor therapeutics inc acquired by millennium pharmaceuticals inc the takeda oncology company b braun interventional and the boc group mr pascoe is a member of the board of directors of kempharm inc as well as a member of the company’s audit and compensation committees and its lead independent director  he also serves as a member of the board of directors of biocom and the johnny mac soldiers fund a charity for military veterans mr pascoe served as a commissioned officer with the us army th infantry division  he is a graduate of the united states military academy at west point where he received a bs degree in leadership brian dorsey senior vice president chief development officer brian t dorsey has been our senior vice president chief development officer since december  mr dorsey has served in the pharmaceutical and biotechnology industries for over  years where he has provided highlevel drug development regulatory and qcqa leadership of pharmaceutical candidates from early development to fda approval he has held various senior management roles with pharmaceutical companies most recently at pernix therapeutics as senior vice president pharmaceutical development from april  to september  mr dorsey held managerial positions of increasing responsibility at somaxon pharmaceuticals from  to  and before that at baxter bioscience and pfizer global research and development mr dorsey received his master of science in executive leadership and his ba in chemistry from the university of san diego neil morton senior vice president chief business officer mr morton brings to apricus a successful track record in business development in specialty pharmaceuticals most recently serving as the executive director of business development at auxilium pharmaceuticals inc where he successfully led their efforts to build a pipeline of men’s health products prior to auxilium pharmaceuticals mr morton served in business development and marketing roles at king pharmaceuticals attaining the position of senior director commercial development mr morton received his mba degree from the babcock graduate school of management at wake forest university and his ba degree in biology from bucknell university mary naggs vice president general counsel mary naggs serves as our vice president general counsel since joining the company in  ms naggs has held various roles with increasing responsibility  she oversees all legal matters including contracts corporate governance employment financing transactions compliance and intellectual property ms naggs graduated summa cum laude from thomas jefferson school of law and she received her bachelor’s degree in biochemistry and cell biology from revelle college university of california at san diego kelly deck executive director finance kelly deck joined the finance team as director of sec reporting in july  prior to apricus ms deck held various roles in the accounting and finance departments for pharmaceutical and biotechnology companies such as at genprobe inc which was acquired by hologic inc in august  as well as la jolla pharmaceutical company inc and cytori therapeutics inc before transitioning to private industry ms deck began her career in  public accounting for a local firm in atlanta georgia ms deck holds a bachelor of business administration in accounting and a master of science in accounting both from the university of cincinnati she is an active licensed cpa in california careers  apricus biosciences search home  careers print this page we are hiring apricus is a pharmaceutical company located in the greater san diego california area that offers outstanding opportunities in pharmaceutical development apricus biosciences inc employs a bestinclass group of professionals with the skills and expertise to operate our business successfully we recognize that a pleasant and productive work environment is an important aspect of our culture and we celebrate individual and companywide performance apricus biosciences inc is an equal employment opportunity eeo employer and makes employment decisions on the basis of merit we vigorously oppose discrimination of any kind company policy prohibits unlawful discrimination based on race color creed gender religion sex national origin ancestry pregnancy age marital status registered domestic partner status sexual orientation medical condition including genetic characteristics physical or mental disability veteran status or any other consideration made unlawful by federal state or local laws this policy also prohibits discrimination based on a perception that anyone has any of those characteristics or is associated with a person who has or is perceived of having any of those characteristics all such discrimination is unlawful this policy applies to all personnel practices including but not limited to recruitment hiring training promotion compensation benefits and transfers apricus biosciences inc complies with all the applicable provisions of the americans with disabilities act ada and does not discriminate against applicants or employees because of physical or mental disability the company will make reasonable accommodations to the extent required by law when requested by employees or applicants with disabilities provided the individual is otherwise qualified to safely perform the essential duties and assignments connected with the job and provided that any accommodation does not impose an undue hardship on the company benefits apricus biosciences inc is committed to providing competitive and high quality benefits for its employees regular fulltime employees are eligible to receive a benefits package including medical dental vision long term disability and life insurance along with those mandated by state and federal law additionally employees receive vacation sick and personal days as well as company assigned paid holidays employees are also eligible to participate in the company’s k retirement program there are currently no job postings apply for position attach resume meet our team i look forward to coming into work every day and its as much about the people as it is about the work itself were a family a team  each individual making a meaningful contribution towards a common goal mary naggs vice president general counsel vitaros™  apricus biosciences search vitaros™ home  pipeline  vitaros™ print this page vitaros™ vitaros™ is a topicallyapplied cream formulation of alprostadil which dilates blood vessels combined with a proprietary permeation enhancer nexact  which directly increases blood flow to the penis causing an erection vitaros™ is currently in development in the us and approved and commercialized in certain countries outside of the us allergan owns the rights to vitaros™ in the us and in september  we entered into an agreement with allergan to license the us development and commercialization rights for vitaros™ ferring international center sa owns the exus rights to vitaros™ pursuant to an asset sales transaction that closed in february  targeting the untreated erectile dysfunction market it is estimated that worldwide  million men suffer with erectile dysfunction factors contributing to the appearance of the disease or its severity include medical history tobacco use and age erectile dysfunction is also found in men with cardiovascular disease other prescription medicines are available for the treatment of erectile dysfunction including phosphodiesterase inhibitors phosphodiesterase inhibitors are effective for the treatment of erectile dysfunction but also have reported side effects such as those that affect the cardiovascular system headaches muscle aches impaired hearing and vision whereas phosphodiesterase inhibitors are taken in the form of a tablet vitaros™ was designed for direct application and to provide a rapid onset with significant efficacy and a favorable safety profile vitaros™ was studied in over  patients and demonstrated positive clinically meaningful responses in measures of erectile function because men with erectile dysfunction often have other diseases vitaros™ was also evaluated in these populations men with erectile dysfunction and accompanying diseases including diabetes cardiovascular disease and prostatectomy also had clinically meaningful enhanced erectile function with vitaros™ vitaros™ was welltolerated in patients including those with additional diseases availability of a locally acting product that is safe and effective addresses an unmet medical need men who are resistant to taking oral medication or have diseases that may preclude them from other treatments now have an alternative with vitaros™ sec filings  investors  apricus biosciences searchhomeinvestor relationssec filingssec filings sec filing keyword search view search tips year filter all yearsgroupings filter view sec groupings descriptionsall formsannual filingscurrent reportsotherproxy filingsquarterly filingsregistration statementsview section  filings  first  previous  next  last filing dateformdescriptionfiling groupdownloadssc ga statement of beneficial ownership of common stock by certain personsother statement of changes in beneficial ownership of securities statement of changes in beneficial ownership of securities statement of changes in beneficial ownership of securities kreport of unscheduled material events or corporate eventcurrent reports ssecurities offered to employees pursuant to employee benefit plansregistration statements kreport of unscheduled material events or corporate eventcurrent reports defaaadditional proxy soliciting materials  definitiveproxy filings qquarterly report which provides a continuing view of a companys financial positionquarterly filings kreport of unscheduled material events or corporate eventcurrent reports sc ga statement of beneficial ownership of common stock by certain personsother kreport of unscheduled material events or corporate eventcurrent reports kreport of unscheduled material events or corporate eventcurrent reports bform of prospectus disclosing information facts events covered in both forms b bregistration statements kreport of unscheduled material events or corporate eventcurrent reports effecteffectother saamended registration statement for faceamount certificate companiesregistration statements kreport of unscheduled material events or corporate eventcurrent reports fwpfwpother saamended registration statement for faceamount certificate companiesregistration statements  first  previous  next  last nsdq  apri    data provided by nasdaqminimum  minutes delayedinvestor relationsinvestor homestock informationnews  eventsfinancialssec filingsfundamentalscorporate governanceshareholder servicestoolkit             investor contactfor further information please contactirapricusbiocom t     institutional  retail investors matthew beck the trout group llcmbecktroutgroupcom t    el camino real suite  san diego ca  t     about apricus  apricus biosciences search we are apricus we are apricus we are apricus home  about apricus print this page about apricus we are committed to the continued development and commercialization of novel therapies addressing unmet medical needs apricus biosciences inc apri is a biopharmaceutical company advancing innovative medicines in urology and rheumatology apricus has two product candidates currently in development vitaros™ is a product candidate in the united states for the treatment of erectile dysfunction which apricus inlicensed from warner chilcott inc now a subsidiary of allergan rayva™ is our product candidate in phase  development for the treatment of circulatory disorder raynaud’s phenomenon secondary to scleroderma which apricus owns worldwide apricus biosciences  wikipedia apricus biosciences from wikipedia the free encyclopedia   redirected from apricus biosciences inc jump to navigation search apricus biosciences inc type public traded as nasdaq apri industry biopharmaceutical founded  headquarters san diego california united states key people richard pascoe ceo brian dorsey isvp  chief development officer barbara troupin md mba svp  chief medical officer products vitaros fispemifene rayva femprox revenue us  million first nine months  number of employees   website  apricus biosciences inc is a san diego based biopharmaceutical company advancing innovative medicines in urology and rheumatology apricus biosciences first product vitaros® has been approved in europe and canada for the treatment of erectile dysfunction other compounds in development include low testosterone rheumatology sexual dysfunction pain contents  history  location  products  nexact technology  leadership  references historyedit until september   when it formally changed its name apricus biosciences inc nasdaq apri had been operating in the pharmaceutical industry since  under the name nexmed inc nasdaqnexm on november   apricus bio received canadian approval for its topical ed treatment vitaros and it announced european approval on june   locationedit apricus biosciences is headquartered in san diego ca the company and its subsidiaries has approximately  employees productsedit vitaros®  is a rapidonset generally – minutes topical cream for the treatment of erectile dysfunction it contains prostaglandin e as the active ingredient and the companys proprietary permeation enhancer nexact® which facilitates the delivery of the drug into the blood stream the current formulation of vitaros requires refrigeration and is delivered via a small individual dispenser vitaros has been approved for patient use in canada and europe and to date january   has been launched by marketing partners in the united kingdom takeda germany sandoz sweden sandoz and belgium sandoz six additional european territories are expected to launch vitaros during  apricus has developed a room temperature formulation of vitaros which is housed and delivered in a small custom developed disposable dispenser or room temperature device rtd initial production of vitaros rtd has commenced in order to generate the required stability data required for marketing approval the company continues to expect its commercial partners to launch the vitaros rtd in  in november  apricus biosciences sold the rights for the refrigerated formulation of vitaros in the us to warner chilcott fispemifene is a new chemical entity initially being pursued for the treatment of low testosterone secondary hypogonadism in males apricus plans to begin a phase b clinical trial with fispemifene in this indication in the first half of  with topline data expected to be reported by the end of  apricus inlicensed the us rights to fispemifene from forendo pharma in q  since then it has transferred the regulatory filings from forendo developed a phase b clinical trial protocol held a scientific advisory board meeting with experts in the field to refine its development strategy initiated the manufacturing process for the drug and begun the clinical trial site selection process rayva™ is a topical cream for the treatment of raynauds phenomenon a circulatory disorder affecting the hands and feet patient enrollment commenced in december  for a patient phase a clinical trial for rayva which is expected to be completed and results announced in the second quarter in  rayva has the potential to be the only fda approved treatment for this debilitating condition rayva contains prostaglandin e as the active ingredient and apricus permeation enhancer nexact which facilitates the delivery of the drug into the blood stream femprox® is a topical cream for the treatment of female sexual interest  arousal disorder it contains prostaglandin e as the active ingredient and a permeation enhancer nexact which facilitates the delivery of the drug into the blood stream nexact technologyedit nexact® is a proprietary watersoluble small molecule permeation enhancer which temporarily changes the permeation dynamics of the lipid bilayer and transiently loosens the tight junctions between the cells so that active drug molecules can be rapidly absorbed into systemic circulation the nexact technology is used in both vitaros and rayva it can also improve the solubility of compounds resulting in enhanced drug permeation leadershipedit richard pascoe  ceo mr pascoe joined apricus in march  following the merger of somaxon pharmaceuticals with pernix at somaxon mr pascoe was the chief executive officer since august  and was responsible for the fda approval of somaxon’s lead drug silenor® prior to somaxon mr pascoe was with ariad pharmaceuticals inc a specialty pharmaceutical company where he was most recently senior vice president and chief operating officer prior to joining ariad in  mr pascoe held a series of senior management roles at king pharmaceuticals inc a specialty pharmaceutical company including senior vice president positions in both marketing and sales as well as vice president positions in both international sales and marketing and hospital sales prior to king mr pascoe was in the commercial groups at medco research inc which was acquired by king cor therapeutics inc b braun interventional and the boc group mr pascoe is a member of the board of directors of kempharm inc cohera medical inc and the corporate directors forum cdf mr pascoe served as a commissioned officer with the us army th infantry division following his graduation from the united states military academy at west point where he received a bs degree in leadership brian dorsey  svp chief development officer mr dorsey has served in the pharmaceutical and biotechnology industries for over  years where he has provided highlevel drug development regulatory and qcqa leadership of pharmaceutical candidates from early development to fda approval he has held various senior management roles with pharmaceutical companies most recently at pernix therapeutics as senior vice president pharmaceutical development prior to this mr dorsey held managerial positions of increasing responsibility at somaxon pharmaceuticals baxter bioscience and pfizer global research and development mr dorsey received his master of science in executive leadership and his ba in chemistry from the university of san diego barbara troupin md mba  svp chief medical officer dr troupin has held various senior management roles with vivus inc in the areas of medical affairs and clinical development since  in these roles dr troupin was the clinician lead for the phase  program for qsymia as well as the lead contributor for all medical review of the qsymia new drug application and was the lead medical presenter at the successful qsymia fda advisory committee meeting prior to this dr troupin held medical director positions at the profil institute for clinical research and radiant research both contract research organizations dr troupin received her md from the university of pennsylvania school of medicine and her mba from the wharton school of business referencesedit  bujdos brian new topical erectile dysfunction drug vitaros approved in canada approved topical drug testim proves helpful for erectile dysfunction archived from the original on  may  retrieved  april    a b apricus sec report sec retrieved  april    release press june   apricus biosciences receives european approval for vitarosr for the treatment of erectile dysfunction apricus biosciences  globenews retrieved  january    release press  apricus biosciences announces yearend  update and  plans to advance its clinical pipeline and further commercialize its erectile dysfunction drug vitarosr apricus biosciences  globenewswire globenewswire retrieved  january    form q disclosure wwwsecgov sec retrieved  january    apricus biosciences inc announces patent grant for femprox in japan reuters  october  retrieved  april    nexact trasdermal drug delivery technology nexact trasdermal drug delivery technology archived from the original on  april  retrieved  april    release press apricus biosciences appoints brian t dorsey as chief development officer wwwapricusbiocom retrieved  january    release press apricus biosciences appoints barbara troupin md as chief medical officer wwwapricusbiocom apricus biosciences retrieved  january   retrieved from httpsenwikipediaorgwindexphptitleapricusbiosciencesoldid categories pharmaceutical companies of the united statesbiotechnology companies of the united statescompanies established in health care companies based in californiahidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view apricus biosciences  wikipedia apricus biosciences from wikipedia the free encyclopedia   redirected from apricus biosciences inc jump to navigation search apricus biosciences inc type public traded as nasdaq apri industry biopharmaceutical founded  headquarters san diego california united states key people richard pascoe ceo brian dorsey isvp  chief development officer barbara troupin md mba svp  chief medical officer products vitaros fispemifene rayva femprox revenue us  million first nine months  number of employees   website  apricus biosciences inc is a san diego based biopharmaceutical company advancing innovative medicines in urology and rheumatology apricus biosciences first product vitaros® has been approved in europe and canada for the treatment of erectile dysfunction other compounds in development include low testosterone rheumatology sexual dysfunction pain contents  history  location  products  nexact technology  leadership  references historyedit until september   when it formally changed its name apricus biosciences inc nasdaq apri had been operating in the pharmaceutical industry since  under the name nexmed inc nasdaqnexm on november   apricus bio received canadian approval for its topical ed treatment vitaros and it announced european approval on june   locationedit apricus biosciences is headquartered in san diego ca the company and its subsidiaries has approximately  employees productsedit vitaros®  is a rapidonset generally – minutes topical cream for the treatment of erectile dysfunction it contains prostaglandin e as the active ingredient and the companys proprietary permeation enhancer nexact® which facilitates the delivery of the drug into the blood stream the current formulation of vitaros requires refrigeration and is delivered via a small individual dispenser vitaros has been approved for patient use in canada and europe and to date january   has been launched by marketing partners in the united kingdom takeda germany sandoz sweden sandoz and belgium sandoz six additional european territories are expected to launch vitaros during  apricus has developed a room temperature formulation of vitaros which is housed and delivered in a small custom developed disposable dispenser or room temperature device rtd initial production of vitaros rtd has commenced in order to generate the required stability data required for marketing approval the company continues to expect its commercial partners to launch the vitaros rtd in  in november  apricus biosciences sold the rights for the refrigerated formulation of vitaros in the us to warner chilcott fispemifene is a new chemical entity initially being pursued for the treatment of low testosterone secondary hypogonadism in males apricus plans to begin a phase b clinical trial with fispemifene in this indication in the first half of  with topline data expected to be reported by the end of  apricus inlicensed the us rights to fispemifene from forendo pharma in q  since then it has transferred the regulatory filings from forendo developed a phase b clinical trial protocol held a scientific advisory board meeting with experts in the field to refine its development strategy initiated the manufacturing process for the drug and begun the clinical trial site selection process rayva™ is a topical cream for the treatment of raynauds phenomenon a circulatory disorder affecting the hands and feet patient enrollment commenced in december  for a patient phase a clinical trial for rayva which is expected to be completed and results announced in the second quarter in  rayva has the potential to be the only fda approved treatment for this debilitating condition rayva contains prostaglandin e as the active ingredient and apricus permeation enhancer nexact which facilitates the delivery of the drug into the blood stream femprox® is a topical cream for the treatment of female sexual interest  arousal disorder it contains prostaglandin e as the active ingredient and a permeation enhancer nexact which facilitates the delivery of the drug into the blood stream nexact technologyedit nexact® is a proprietary watersoluble small molecule permeation enhancer which temporarily changes the permeation dynamics of the lipid bilayer and transiently loosens the tight junctions between the cells so that active drug molecules can be rapidly absorbed into systemic circulation the nexact technology is used in both vitaros and rayva it can also improve the solubility of compounds resulting in enhanced drug permeation leadershipedit richard pascoe  ceo mr pascoe joined apricus in march  following the merger of somaxon pharmaceuticals with pernix at somaxon mr pascoe was the chief executive officer since august  and was responsible for the fda approval of somaxon’s lead drug silenor® prior to somaxon mr pascoe was with ariad pharmaceuticals inc a specialty pharmaceutical company where he was most recently senior vice president and chief operating officer prior to joining ariad in  mr pascoe held a series of senior management roles at king pharmaceuticals inc a specialty pharmaceutical company including senior vice president positions in both marketing and sales as well as vice president positions in both international sales and marketing and hospital sales prior to king mr pascoe was in the commercial groups at medco research inc which was acquired by king cor therapeutics inc b braun interventional and the boc group mr pascoe is a member of the board of directors of kempharm inc cohera medical inc and the corporate directors forum cdf mr pascoe served as a commissioned officer with the us army th infantry division following his graduation from the united states military academy at west point where he received a bs degree in leadership brian dorsey  svp chief development officer mr dorsey has served in the pharmaceutical and biotechnology industries for over  years where he has provided highlevel drug development regulatory and qcqa leadership of pharmaceutical candidates from early development to fda approval he has held various senior management roles with pharmaceutical companies most recently at pernix therapeutics as senior vice president pharmaceutical development prior to this mr dorsey held managerial positions of increasing responsibility at somaxon pharmaceuticals baxter bioscience and pfizer global research and development mr dorsey received his master of science in executive leadership and his ba in chemistry from the university of san diego barbara troupin md mba  svp chief medical officer dr troupin has held various senior management roles with vivus inc in the areas of medical affairs and clinical development since  in these roles dr troupin was the clinician lead for the phase  program for qsymia as well as the lead contributor for all medical review of the qsymia new drug application and was the lead medical presenter at the successful qsymia fda advisory committee meeting prior to this dr troupin held medical director positions at the profil institute for clinical research and radiant research both contract research organizations dr troupin received her md from the university of pennsylvania school of medicine and her mba from the wharton school of business referencesedit  bujdos brian new topical erectile dysfunction drug vitaros approved in canada approved topical drug testim proves helpful for erectile dysfunction archived from the original on  may  retrieved  april    a b apricus sec report sec retrieved  april    release press june   apricus biosciences receives european approval for vitarosr for the treatment of erectile dysfunction apricus biosciences  globenews retrieved  january    release press  apricus biosciences announces yearend  update and  plans to advance its clinical pipeline and further commercialize its erectile dysfunction drug vitarosr apricus biosciences  globenewswire globenewswire retrieved  january    form q disclosure wwwsecgov sec retrieved  january    apricus biosciences inc announces patent grant for femprox in japan reuters  october  retrieved  april    nexact trasdermal drug delivery technology nexact trasdermal drug delivery technology archived from the original on  april  retrieved  april    release press apricus biosciences appoints brian t dorsey as chief development officer wwwapricusbiocom retrieved  january    release press apricus biosciences appoints barbara troupin md as chief medical officer wwwapricusbiocom apricus biosciences retrieved  january   retrieved from httpsenwikipediaorgwindexphptitleapricusbiosciencesoldid categories pharmaceutical companies of the united statesbiotechnology companies of the united statescompanies established in health care companies based in californiahidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view apricus biosciences  wikipedia apricus biosciences from wikipedia the free encyclopedia   redirected from apricus biosciences inc jump to navigation search apricus biosciences inc type public traded as nasdaq apri industry biopharmaceutical founded  headquarters san diego california united states key people richard pascoe ceo brian dorsey isvp  chief development officer barbara troupin md mba svp  chief medical officer products vitaros fispemifene rayva femprox revenue us  million first nine months  number of employees   website  apricus biosciences inc is a san diego based biopharmaceutical company advancing innovative medicines in urology and rheumatology apricus biosciences first product vitaros® has been approved in europe and canada for the treatment of erectile dysfunction other compounds in development include low testosterone rheumatology sexual dysfunction pain contents  history  location  products  nexact technology  leadership  references historyedit until september   when it formally changed its name apricus biosciences inc nasdaq apri had been operating in the pharmaceutical industry since  under the name nexmed inc nasdaqnexm on november   apricus bio received canadian approval for its topical ed treatment vitaros and it announced european approval on june   locationedit apricus biosciences is headquartered in san diego ca the company and its subsidiaries has approximately  employees productsedit vitaros®  is a rapidonset generally – minutes topical cream for the treatment of erectile dysfunction it contains prostaglandin e as the active ingredient and the companys proprietary permeation enhancer nexact® which facilitates the delivery of the drug into the blood stream the current formulation of vitaros requires refrigeration and is delivered via a small individual dispenser vitaros has been approved for patient use in canada and europe and to date january   has been launched by marketing partners in the united kingdom takeda germany sandoz sweden sandoz and belgium sandoz six additional european territories are expected to launch vitaros during  apricus has developed a room temperature formulation of vitaros which is housed and delivered in a small custom developed disposable dispenser or room temperature device rtd initial production of vitaros rtd has commenced in order to generate the required stability data required for marketing approval the company continues to expect its commercial partners to launch the vitaros rtd in  in november  apricus biosciences sold the rights for the refrigerated formulation of vitaros in the us to warner chilcott fispemifene is a new chemical entity initially being pursued for the treatment of low testosterone secondary hypogonadism in males apricus plans to begin a phase b clinical trial with fispemifene in this indication in the first half of  with topline data expected to be reported by the end of  apricus inlicensed the us rights to fispemifene from forendo pharma in q  since then it has transferred the regulatory filings from forendo developed a phase b clinical trial protocol held a scientific advisory board meeting with experts in the field to refine its development strategy initiated the manufacturing process for the drug and begun the clinical trial site selection process rayva™ is a topical cream for the treatment of raynauds phenomenon a circulatory disorder affecting the hands and feet patient enrollment commenced in december  for a patient phase a clinical trial for rayva which is expected to be completed and results announced in the second quarter in  rayva has the potential to be the only fda approved treatment for this debilitating condition rayva contains prostaglandin e as the active ingredient and apricus permeation enhancer nexact which facilitates the delivery of the drug into the blood stream femprox® is a topical cream for the treatment of female sexual interest  arousal disorder it contains prostaglandin e as the active ingredient and a permeation enhancer nexact which facilitates the delivery of the drug into the blood stream nexact technologyedit nexact® is a proprietary watersoluble small molecule permeation enhancer which temporarily changes the permeation dynamics of the lipid bilayer and transiently loosens the tight junctions between the cells so that active drug molecules can be rapidly absorbed into systemic circulation the nexact technology is used in both vitaros and rayva it can also improve the solubility of compounds resulting in enhanced drug permeation leadershipedit richard pascoe  ceo mr pascoe joined apricus in march  following the merger of somaxon pharmaceuticals with pernix at somaxon mr pascoe was the chief executive officer since august  and was responsible for the fda approval of somaxon’s lead drug silenor® prior to somaxon mr pascoe was with ariad pharmaceuticals inc a specialty pharmaceutical company where he was most recently senior vice president and chief operating officer prior to joining ariad in  mr pascoe held a series of senior management roles at king pharmaceuticals inc a specialty pharmaceutical company including senior vice president positions in both marketing and sales as well as vice president positions in both international sales and marketing and hospital sales prior to king mr pascoe was in the commercial groups at medco research inc which was acquired by king cor therapeutics inc b braun interventional and the boc group mr pascoe is a member of the board of directors of kempharm inc cohera medical inc and the corporate directors forum cdf mr pascoe served as a commissioned officer with the us army th infantry division following his graduation from the united states military academy at west point where he received a bs degree in leadership brian dorsey  svp chief development officer mr dorsey has served in the pharmaceutical and biotechnology industries for over  years where he has provided highlevel drug development regulatory and qcqa leadership of pharmaceutical candidates from early development to fda approval he has held various senior management roles with pharmaceutical companies most recently at pernix therapeutics as senior vice president pharmaceutical development prior to this mr dorsey held managerial positions of increasing responsibility at somaxon pharmaceuticals baxter bioscience and pfizer global research and development mr dorsey received his master of science in executive leadership and his ba in chemistry from the university of san diego barbara troupin md mba  svp chief medical officer dr troupin has held various senior management roles with vivus inc in the areas of medical affairs and clinical development since  in these roles dr troupin was the clinician lead for the phase  program for qsymia as well as the lead contributor for all medical review of the qsymia new drug application and was the lead medical presenter at the successful qsymia fda advisory committee meeting prior to this dr troupin held medical director positions at the profil institute for clinical research and radiant research both contract research organizations dr troupin received her md from the university of pennsylvania school of medicine and her mba from the wharton school of business referencesedit  bujdos brian new topical erectile dysfunction drug vitaros approved in canada approved topical drug testim proves helpful for erectile dysfunction archived from the original on  may  retrieved  april    a b apricus sec report sec retrieved  april    release press june   apricus biosciences receives european approval for vitarosr for the treatment of erectile dysfunction apricus biosciences  globenews retrieved  january    release press  apricus biosciences announces yearend  update and  plans to advance its clinical pipeline and further commercialize its erectile dysfunction drug vitarosr apricus biosciences  globenewswire globenewswire retrieved  january    form q disclosure wwwsecgov sec retrieved  january    apricus biosciences inc announces patent grant for femprox in japan reuters  october  retrieved  april    nexact trasdermal drug delivery technology nexact trasdermal drug delivery technology archived from the original on  april  retrieved  april    release press apricus biosciences appoints brian t dorsey as chief development officer wwwapricusbiocom retrieved  january    release press apricus biosciences appoints barbara troupin md as chief medical officer wwwapricusbiocom apricus biosciences retrieved  january   retrieved from httpsenwikipediaorgwindexphptitleapricusbiosciencesoldid categories pharmaceutical companies of the united statesbiotechnology companies of the united statescompanies established in health care companies based in californiahidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view apricus biosciences  wikipedia apricus biosciences from wikipedia the free encyclopedia   redirected from apricus biosciences inc jump to navigation search apricus biosciences inc type public traded as nasdaq apri industry biopharmaceutical founded  headquarters san diego california united states key people richard pascoe ceo brian dorsey isvp  chief development officer barbara troupin md mba svp  chief medical officer products vitaros fispemifene rayva femprox revenue us  million first nine months  number of employees   website  apricus biosciences inc is a san diego based biopharmaceutical company advancing innovative medicines in urology and rheumatology apricus biosciences first product vitaros® has been approved in europe and canada for the treatment of erectile dysfunction other compounds in development include low testosterone rheumatology sexual dysfunction pain contents  history  location  products  nexact technology  leadership  references historyedit until september   when it formally changed its name apricus biosciences inc nasdaq apri had been operating in the pharmaceutical industry since  under the name nexmed inc nasdaqnexm on november   apricus bio received canadian approval for its topical ed treatment vitaros and it announced european approval on june   locationedit apricus biosciences is headquartered in san diego ca the company and its subsidiaries has approximately  employees productsedit vitaros®  is a rapidonset generally – minutes topical cream for the treatment of erectile dysfunction it contains prostaglandin e as the active ingredient and the companys proprietary permeation enhancer nexact® which facilitates the delivery of the drug into the blood stream the current formulation of vitaros requires refrigeration and is delivered via a small individual dispenser vitaros has been approved for patient use in canada and europe and to date january   has been launched by marketing partners in the united kingdom takeda germany sandoz sweden sandoz and belgium sandoz six additional european territories are expected to launch vitaros during  apricus has developed a room temperature formulation of vitaros which is housed and delivered in a small custom developed disposable dispenser or room temperature device rtd initial production of vitaros rtd has commenced in order to generate the required stability data required for marketing approval the company continues to expect its commercial partners to launch the vitaros rtd in  in november  apricus biosciences sold the rights for the refrigerated formulation of vitaros in the us to warner chilcott fispemifene is a new chemical entity initially being pursued for the treatment of low testosterone secondary hypogonadism in males apricus plans to begin a phase b clinical trial with fispemifene in this indication in the first half of  with topline data expected to be reported by the end of  apricus inlicensed the us rights to fispemifene from forendo pharma in q  since then it has transferred the regulatory filings from forendo developed a phase b clinical trial protocol held a scientific advisory board meeting with experts in the field to refine its development strategy initiated the manufacturing process for the drug and begun the clinical trial site selection process rayva™ is a topical cream for the treatment of raynauds phenomenon a circulatory disorder affecting the hands and feet patient enrollment commenced in december  for a patient phase a clinical trial for rayva which is expected to be completed and results announced in the second quarter in  rayva has the potential to be the only fda approved treatment for this debilitating condition rayva contains prostaglandin e as the active ingredient and apricus permeation enhancer nexact which facilitates the delivery of the drug into the blood stream femprox® is a topical cream for the treatment of female sexual interest  arousal disorder it contains prostaglandin e as the active ingredient and a permeation enhancer nexact which facilitates the delivery of the drug into the blood stream nexact technologyedit nexact® is a proprietary watersoluble small molecule permeation enhancer which temporarily changes the permeation dynamics of the lipid bilayer and transiently loosens the tight junctions between the cells so that active drug molecules can be rapidly absorbed into systemic circulation the nexact technology is used in both vitaros and rayva it can also improve the solubility of compounds resulting in enhanced drug permeation leadershipedit richard pascoe  ceo mr pascoe joined apricus in march  following the merger of somaxon pharmaceuticals with pernix at somaxon mr pascoe was the chief executive officer since august  and was responsible for the fda approval of somaxon’s lead drug silenor® prior to somaxon mr pascoe was with ariad pharmaceuticals inc a specialty pharmaceutical company where he was most recently senior vice president and chief operating officer prior to joining ariad in  mr pascoe held a series of senior management roles at king pharmaceuticals inc a specialty pharmaceutical company including senior vice president positions in both marketing and sales as well as vice president positions in both international sales and marketing and hospital sales prior to king mr pascoe was in the commercial groups at medco research inc which was acquired by king cor therapeutics inc b braun interventional and the boc group mr pascoe is a member of the board of directors of kempharm inc cohera medical inc and the corporate directors forum cdf mr pascoe served as a commissioned officer with the us army th infantry division following his graduation from the united states military academy at west point where he received a bs degree in leadership brian dorsey  svp chief development officer mr dorsey has served in the pharmaceutical and biotechnology industries for over  years where he has provided highlevel drug development regulatory and qcqa leadership of pharmaceutical candidates from early development to fda approval he has held various senior management roles with pharmaceutical companies most recently at pernix therapeutics as senior vice president pharmaceutical development prior to this mr dorsey held managerial positions of increasing responsibility at somaxon pharmaceuticals baxter bioscience and pfizer global research and development mr dorsey received his master of science in executive leadership and his ba in chemistry from the university of san diego barbara troupin md mba  svp chief medical officer dr troupin has held various senior management roles with vivus inc in the areas of medical affairs and clinical development since  in these roles dr troupin was the clinician lead for the phase  program for qsymia as well as the lead contributor for all medical review of the qsymia new drug application and was the lead medical presenter at the successful qsymia fda advisory committee meeting prior to this dr troupin held medical director positions at the profil institute for clinical research and radiant research both contract research organizations dr troupin received her md from the university of pennsylvania school of medicine and her mba from the wharton school of business referencesedit  bujdos brian new topical erectile dysfunction drug vitaros approved in canada approved topical drug testim proves helpful for erectile dysfunction archived from the original on  may  retrieved  april    a b apricus sec report sec retrieved  april    release press june   apricus biosciences receives european approval for vitarosr for the treatment of erectile dysfunction apricus biosciences  globenews retrieved  january    release press  apricus biosciences announces yearend  update and  plans to advance its clinical pipeline and further commercialize its erectile dysfunction drug vitarosr apricus biosciences  globenewswire globenewswire retrieved  january    form q disclosure wwwsecgov sec retrieved  january    apricus biosciences inc announces patent grant for femprox in japan reuters  october  retrieved  april    nexact trasdermal drug delivery technology nexact trasdermal drug delivery technology archived from the original on  april  retrieved  april    release press apricus biosciences appoints brian t dorsey as chief development officer wwwapricusbiocom retrieved  january    release press apricus biosciences appoints barbara troupin md as chief medical officer wwwapricusbiocom apricus biosciences retrieved  january   retrieved from httpsenwikipediaorgwindexphptitleapricusbiosciencesoldid categories pharmaceutical companies of the united statesbiotechnology companies of the united statescompanies established in health care companies based in californiahidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view apricus biosciences  wikipedia apricus biosciences from wikipedia the free encyclopedia   redirected from apricus biosciences inc jump to navigation search apricus biosciences inc type public traded as nasdaq apri industry biopharmaceutical founded  headquarters san diego california united states key people richard pascoe ceo brian dorsey isvp  chief development officer barbara troupin md mba svp  chief medical officer products vitaros fispemifene rayva femprox revenue us  million first nine months  number of employees   website  apricus biosciences inc is a san diego based biopharmaceutical company advancing innovative medicines in urology and rheumatology apricus biosciences first product vitaros® has been approved in europe and canada for the treatment of erectile dysfunction other compounds in development include low testosterone rheumatology sexual dysfunction pain contents  history  location  products  nexact technology  leadership  references historyedit until september   when it formally changed its name apricus biosciences inc nasdaq apri had been operating in the pharmaceutical industry since  under the name nexmed inc nasdaqnexm on november   apricus bio received canadian approval for its topical ed treatment vitaros and it announced european approval on june   locationedit apricus biosciences is headquartered in san diego ca the company and its subsidiaries has approximately  employees productsedit vitaros®  is a rapidonset generally – minutes topical cream for the treatment of erectile dysfunction it contains prostaglandin e as the active ingredient and the companys proprietary permeation enhancer nexact® which facilitates the delivery of the drug into the blood stream the current formulation of vitaros requires refrigeration and is delivered via a small individual dispenser vitaros has been approved for patient use in canada and europe and to date january   has been launched by marketing partners in the united kingdom takeda germany sandoz sweden sandoz and belgium sandoz six additional european territories are expected to launch vitaros during  apricus has developed a room temperature formulation of vitaros which is housed and delivered in a small custom developed disposable dispenser or room temperature device rtd initial production of vitaros rtd has commenced in order to generate the required stability data required for marketing approval the company continues to expect its commercial partners to launch the vitaros rtd in  in november  apricus biosciences sold the rights for the refrigerated formulation of vitaros in the us to warner chilcott fispemifene is a new chemical entity initially being pursued for the treatment of low testosterone secondary hypogonadism in males apricus plans to begin a phase b clinical trial with fispemifene in this indication in the first half of  with topline data expected to be reported by the end of  apricus inlicensed the us rights to fispemifene from forendo pharma in q  since then it has transferred the regulatory filings from forendo developed a phase b clinical trial protocol held a scientific advisory board meeting with experts in the field to refine its development strategy initiated the manufacturing process for the drug and begun the clinical trial site selection process rayva™ is a topical cream for the treatment of raynauds phenomenon a circulatory disorder affecting the hands and feet patient enrollment commenced in december  for a patient phase a clinical trial for rayva which is expected to be completed and results announced in the second quarter in  rayva has the potential to be the only fda approved treatment for this debilitating condition rayva contains prostaglandin e as the active ingredient and apricus permeation enhancer nexact which facilitates the delivery of the drug into the blood stream femprox® is a topical cream for the treatment of female sexual interest  arousal disorder it contains prostaglandin e as the active ingredient and a permeation enhancer nexact which facilitates the delivery of the drug into the blood stream nexact technologyedit nexact® is a proprietary watersoluble small molecule permeation enhancer which temporarily changes the permeation dynamics of the lipid bilayer and transiently loosens the tight junctions between the cells so that active drug molecules can be rapidly absorbed into systemic circulation the nexact technology is used in both vitaros and rayva it can also improve the solubility of compounds resulting in enhanced drug permeation leadershipedit richard pascoe  ceo mr pascoe joined apricus in march  following the merger of somaxon pharmaceuticals with pernix at somaxon mr pascoe was the chief executive officer since august  and was responsible for the fda approval of somaxon’s lead drug silenor® prior to somaxon mr pascoe was with ariad pharmaceuticals inc a specialty pharmaceutical company where he was most recently senior vice president and chief operating officer prior to joining ariad in  mr pascoe held a series of senior management roles at king pharmaceuticals inc a specialty pharmaceutical company including senior vice president positions in both marketing and sales as well as vice president positions in both international sales and marketing and hospital sales prior to king mr pascoe was in the commercial groups at medco research inc which was acquired by king cor therapeutics inc b braun interventional and the boc group mr pascoe is a member of the board of directors of kempharm inc cohera medical inc and the corporate directors forum cdf mr pascoe served as a commissioned officer with the us army th infantry division following his graduation from the united states military academy at west point where he received a bs degree in leadership brian dorsey  svp chief development officer mr dorsey has served in the pharmaceutical and biotechnology industries for over  years where he has provided highlevel drug development regulatory and qcqa leadership of pharmaceutical candidates from early development to fda approval he has held various senior management roles with pharmaceutical companies most recently at pernix therapeutics as senior vice president pharmaceutical development prior to this mr dorsey held managerial positions of increasing responsibility at somaxon pharmaceuticals baxter bioscience and pfizer global research and development mr dorsey received his master of science in executive leadership and his ba in chemistry from the university of san diego barbara troupin md mba  svp chief medical officer dr troupin has held various senior management roles with vivus inc in the areas of medical affairs and clinical development since  in these roles dr troupin was the clinician lead for the phase  program for qsymia as well as the lead contributor for all medical review of the qsymia new drug application and was the lead medical presenter at the successful qsymia fda advisory committee meeting prior to this dr troupin held medical director positions at the profil institute for clinical research and radiant research both contract research organizations dr troupin received her md from the university of pennsylvania school of medicine and her mba from the wharton school of business referencesedit  bujdos brian new topical erectile dysfunction drug vitaros approved in canada approved topical drug testim proves helpful for erectile dysfunction archived from the original on  may  retrieved  april    a b apricus sec report sec retrieved  april    release press june   apricus biosciences receives european approval for vitarosr for the treatment of erectile dysfunction apricus biosciences  globenews retrieved  january    release press  apricus biosciences announces yearend  update and  plans to advance its clinical pipeline and further commercialize its erectile dysfunction drug vitarosr apricus biosciences  globenewswire globenewswire retrieved  january    form q disclosure wwwsecgov sec retrieved  january    apricus biosciences inc announces patent grant for femprox in japan reuters  october  retrieved  april    nexact trasdermal drug delivery technology nexact trasdermal drug delivery technology archived from the original on  april  retrieved  april    release press apricus biosciences appoints brian t dorsey as chief development officer wwwapricusbiocom retrieved  january    release press apricus biosciences appoints barbara troupin md as chief medical officer wwwapricusbiocom apricus biosciences retrieved  january   retrieved from httpsenwikipediaorgwindexphptitleapricusbiosciencesoldid categories pharmaceutical companies of the united statesbiotechnology companies of the united statescompanies established in health care companies based in californiahidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view apricus biosciences  wikipedia apricus biosciences from wikipedia the free encyclopedia   redirected from apricus biosciences inc jump to navigation search apricus biosciences inc type public traded as nasdaq apri industry biopharmaceutical founded  headquarters san diego california united states key people richard pascoe ceo brian dorsey isvp  chief development officer barbara troupin md mba svp  chief medical officer products vitaros fispemifene rayva femprox revenue us  million first nine months  number of employees   website  apricus biosciences inc is a san diego based biopharmaceutical company advancing innovative medicines in urology and rheumatology apricus biosciences first product vitaros® has been approved in europe and canada for the treatment of erectile dysfunction other compounds in development include low testosterone rheumatology sexual dysfunction pain contents  history  location  products  nexact technology  leadership  references historyedit until september   when it formally changed its name apricus biosciences inc nasdaq apri had been operating in the pharmaceutical industry since  under the name nexmed inc nasdaqnexm on november   apricus bio received canadian approval for its topical ed treatment vitaros and it announced european approval on june   locationedit apricus biosciences is headquartered in san diego ca the company and its subsidiaries has approximately  employees productsedit vitaros®  is a rapidonset generally – minutes topical cream for the treatment of erectile dysfunction it contains prostaglandin e as the active ingredient and the companys proprietary permeation enhancer nexact® which facilitates the delivery of the drug into the blood stream the current formulation of vitaros requires refrigeration and is delivered via a small individual dispenser vitaros has been approved for patient use in canada and europe and to date january   has been launched by marketing partners in the united kingdom takeda germany sandoz sweden sandoz and belgium sandoz six additional european territories are expected to launch vitaros during  apricus has developed a room temperature formulation of vitaros which is housed and delivered in a small custom developed disposable dispenser or room temperature device rtd initial production of vitaros rtd has commenced in order to generate the required stability data required for marketing approval the company continues to expect its commercial partners to launch the vitaros rtd in  in november  apricus biosciences sold the rights for the refrigerated formulation of vitaros in the us to warner chilcott fispemifene is a new chemical entity initially being pursued for the treatment of low testosterone secondary hypogonadism in males apricus plans to begin a phase b clinical trial with fispemifene in this indication in the first half of  with topline data expected to be reported by the end of  apricus inlicensed the us rights to fispemifene from forendo pharma in q  since then it has transferred the regulatory filings from forendo developed a phase b clinical trial protocol held a scientific advisory board meeting with experts in the field to refine its development strategy initiated the manufacturing process for the drug and begun the clinical trial site selection process rayva™ is a topical cream for the treatment of raynauds phenomenon a circulatory disorder affecting the hands and feet patient enrollment commenced in december  for a patient phase a clinical trial for rayva which is expected to be completed and results announced in the second quarter in  rayva has the potential to be the only fda approved treatment for this debilitating condition rayva contains prostaglandin e as the active ingredient and apricus permeation enhancer nexact which facilitates the delivery of the drug into the blood stream femprox® is a topical cream for the treatment of female sexual interest  arousal disorder it contains prostaglandin e as the active ingredient and a permeation enhancer nexact which facilitates the delivery of the drug into the blood stream nexact technologyedit nexact® is a proprietary watersoluble small molecule permeation enhancer which temporarily changes the permeation dynamics of the lipid bilayer and transiently loosens the tight junctions between the cells so that active drug molecules can be rapidly absorbed into systemic circulation the nexact technology is used in both vitaros and rayva it can also improve the solubility of compounds resulting in enhanced drug permeation leadershipedit richard pascoe  ceo mr pascoe joined apricus in march  following the merger of somaxon pharmaceuticals with pernix at somaxon mr pascoe was the chief executive officer since august  and was responsible for the fda approval of somaxon’s lead drug silenor® prior to somaxon mr pascoe was with ariad pharmaceuticals inc a specialty pharmaceutical company where he was most recently senior vice president and chief operating officer prior to joining ariad in  mr pascoe held a series of senior management roles at king pharmaceuticals inc a specialty pharmaceutical company including senior vice president positions in both marketing and sales as well as vice president positions in both international sales and marketing and hospital sales prior to king mr pascoe was in the commercial groups at medco research inc which was acquired by king cor therapeutics inc b braun interventional and the boc group mr pascoe is a member of the board of directors of kempharm inc cohera medical inc and the corporate directors forum cdf mr pascoe served as a commissioned officer with the us army th infantry division following his graduation from the united states military academy at west point where he received a bs degree in leadership brian dorsey  svp chief development officer mr dorsey has served in the pharmaceutical and biotechnology industries for over  years where he has provided highlevel drug development regulatory and qcqa leadership of pharmaceutical candidates from early development to fda approval he has held various senior management roles with pharmaceutical companies most recently at pernix therapeutics as senior vice president pharmaceutical development prior to this mr dorsey held managerial positions of increasing responsibility at somaxon pharmaceuticals baxter bioscience and pfizer global research and development mr dorsey received his master of science in executive leadership and his ba in chemistry from the university of san diego barbara troupin md mba  svp chief medical officer dr troupin has held various senior management roles with vivus inc in the areas of medical affairs and clinical development since  in these roles dr troupin was the clinician lead for the phase  program for qsymia as well as the lead contributor for all medical review of the qsymia new drug application and was the lead medical presenter at the successful qsymia fda advisory committee meeting prior to this dr troupin held medical director positions at the profil institute for clinical research and radiant research both contract research organizations dr troupin received her md from the university of pennsylvania school of medicine and her mba from the wharton school of business referencesedit  bujdos brian new topical erectile dysfunction drug vitaros approved in canada approved topical drug testim proves helpful for erectile dysfunction archived from the original on  may  retrieved  april    a b apricus sec report sec retrieved  april    release press june   apricus biosciences receives european approval for vitarosr for the treatment of erectile dysfunction apricus biosciences  globenews retrieved  january    release press  apricus biosciences announces yearend  update and  plans to advance its clinical pipeline and further commercialize its erectile dysfunction drug vitarosr apricus biosciences  globenewswire globenewswire retrieved  january    form q disclosure wwwsecgov sec retrieved  january    apricus biosciences inc announces patent grant for femprox in japan reuters  october  retrieved  april    nexact trasdermal drug delivery technology nexact trasdermal drug delivery technology archived from the original on  april  retrieved  april    release press apricus biosciences appoints brian t dorsey as chief development officer wwwapricusbiocom retrieved  january    release press apricus biosciences appoints barbara troupin md as chief medical officer wwwapricusbiocom apricus biosciences retrieved  january   retrieved from httpsenwikipediaorgwindexphptitleapricusbiosciencesoldid categories pharmaceutical companies of the united statesbiotechnology companies of the united statescompanies established in health care companies based in californiahidden categories pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view aprinasdaq cm stock quote  apricus biosciences inc  bloomberg markets error could not add to watchlist x  watchlist apricus biosciences inc aprius nasdaq cm usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  apricus biosciences sells ed therapy rights  investopedia there are currently no news stories for this ticker please check back later  erectile dysfunction pipeline drugs and therapeutics market h  available at rnr market research  forge therapeutics attracts biotechnology leaders to join expanded board of directors  apricus biosciences inc apricus biosciences provides corporate update and first quarter  financial results  apricus biosciences provides corporate update and first quarter  financial results  apricus biosciences inc apricus biosciences announces the initiation of vitaros drugdevice human factors study  apricus biosciences announces the initiation of vitaros drugdevice human factors study  apricus biosciences inc apricus biosciences announces corporate update and first quarter  financial results conference  apricus biosciences announces corporate update and first quarter  financial results conference call  apricus biosciences inc apricus biosciences regains compliance with nasdaq continued listing requirements  apricus biosciences regains compliance with nasdaq continued listing requirements there are currently no press releases for this ticker please check back later profile apricus biosciences inc is a biotechnology company the company is seeking to monetize its existing product pipeline including compounds from preclinical through phase  currently focused on dermatology sexual dysfunction and cancer address  el camino realsuite san diego ca united states phone  website wwwapricusbiocom executives board members richard w pascoe ceosecretary brian t dorsey senior vp chief dev ofcr mary naggs vpgeneral counsel neil morton senior vpchief business ofcr kelly deck exec dirfinance show more apri key statistics  apricus biosciences inc financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close apricus biosciences inc nasdaq apri go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus apricus biosciences inc market closed  quotes are delayed by  min jul    pm apri quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description apricus biosciences inc is a pharmaceutical company focus on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology the company products include vitaros and femprox it operates through pharmaceutical segment which designs and  apricus biosciences inc is a pharmaceutical company focus on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology the company products include vitaros and femprox it operates through pharmaceutical segment which designs and develops pharmaceutical products including those with its nexact platform apricus biosciences was founded in  and is headquartered in san diego ca valuation pe current  pe ratio with extraordinary items  price to sales ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  capital structure total debt to total assets  officers and executives name age officer since title dr kleanthis g xanthopoulos   chairman mr richard w pascoe   chief executive officer cao secretary  director mr neil c morton   chief business officer  senior vice president mr brian t dorsey   chief development officer  senior vice president ms mary naggs   general counsel  vice president insider actions – purchase – sale  – number of transactions  newslatestcompanyusapri marketwatch news on apri  cheapest stocks in the nasdaq’s hottest sector  pm feb    philip van doorn  stocks that are pushing the nasdaq to   pm feb    philip van doorn apricus biosciences up  in premarket  am oct    steve gelsi thursday’s biggest gaining and declining stocks  pm sept    marketwatch apricus prices stock offering at  discount  am feb    marketwatchcom drug stocks mixed regeneron rallies  pm nov    val brickates kennedy apricus rockets on liver cancer drug update  am nov    val brickates kennedy updates advisories and surprises  pm sept    marketwatch apricus biosciences drops  after unit offering  am sept    steve gelsi newsnonmarketwatchcompanyusapri other news on apri apricus biosciences apri ceo richard pascoe on q  results  earnings call transcript  pm may    seeking alpha q apricus biosciences inc  pm may    edgar online  edg  q k charles brandes invests in health care in st quarter  am may    gurufocuscom esterline technologies corporation esl leads  notable investor filings  pm may    investorplacecom apricus prices equity offering at unit shares off  premarket  am april    seeking alpha apricus biosciences apri ceo richard pascoe on q  results  earnings call transcript  pm march    seeking alpha k apricus biosciences inc  pm march    edgar online  edg  q k  stocks to watch on thursday snap inc snap apricus biosciences inc apri and elf beauty inc elf  am march    investorplacecom apricus completes sale of exus rights to vitaros to ferring  pm march    seeking alpha apricus apri stock gains on vitaros approval in mexico  am jan    zackscom apricus biosciences inc apri stock scores win on vitaros approval  pm jan    investorplacecom apricus bios topical ed cream okd in mexico shares gallop   pm jan    seeking alpha apricus launches vitaros in lebanon for erectile dysfunction  am dec    zackscom zackscom featured highlights baxter international mam software group advanced energy industries apricus biosciences and copart  am dec    zackscom apricus apri presents at ld micro main event  pm dec    seeking alpha  efficient stocks to buy for superlative returns  am dec    zackscom apricus bio faces delisting from nasdaq  am dec    seeking alpha apricus biosciences aims to resubmit vitaros nda in   am nov    zackscom apricus bio expects to resubmit vitaros nda next year now considered drugdevice combination shares down  premarket  am nov    seeking alpha apricus biosciences inc  q  results  earnings call slides  pm nov    seeking alpha loading more headlines at a glance apricus biosciences inc  el camino real suite  san diego california  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for apri newspressreleasecompanyusapri press releases on apri daily technical summary reports on drug makers stocks  apricus biosciences durect sucampo pharma and sciclone pharma  am june    pr newswire  prf technical reports on drug makers stocks  synergy pharma novo nordisk apricus biosciences and sucampo pharma  am may    pr newswire  prf apricus biosciences provides corporate update and first quarter  financial results  pm may    globenewswire apricus biosciences provides corporate update and first quarter  financial results  pm may    globe newswire investor network apricus biosciences inc to host earnings call  pm may    accesswire apricus biosciences announces the initiation of vitaros drugdevice human factors study  am may    globenewswire apricus biosciences announces the initiation of vitaros drugdevice human factors study  am may    globe newswire apricus biosciences announces corporate update and first quarter  financial results conference call  am may    globenewswire apricus biosciences announces corporate update and first quarter  financial results conference call  am may    globe newswire apricus biosciences regains compliance with nasdaq continued listing requirements  pm may    globenewswire apricus biosciences regains compliance with nasdaq continued listing requirements  pm may    globe newswire apricus biosciences announces pricing of  million public offering  am april    globe newswire apricus biosciences announces pricing of  million public offering  am april    globenewswire apricus biosciences and protalix biotherapeutics seeing opposite sides of fda clinical trials  am april    accesswire drug makers stocks under scanner  synergy pharma novo nordisk apricus biosciences and sucampo pharma  am april    pr newswire  prf apricus biosciences provides corporate update fourth quarter and full year  financial results  pm march    globe newswire apricus biosciences provides corporate update fourth quarter and full year  financial results  pm march    globenewswire apricus biosciences announces corporate update fourth quarter and full year  financial results conference call  am march    globe newswire apricus biosciences announces corporate update fourth quarter and full year  financial results conference call  am march    globenewswire apricus biosciences announces sale of exus vitaros assets and rights to ferring pharmaceuticals  pm march    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ptrump says he has ‘complete power to pardon’ plawmakers reach deal on russia sanctions bill reports palphabet earnings a  billion hit for google potential youtube results for investors pyou can date someone who looks just like donald trump with this new online service pwant to buy happiness splurge on these  things pthis is what people really buy when they emotionally overspend hint it’s not designer clothes pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pi want to buy my brothers out of our family home — but they want me to pay future sales fees poj simpson made over  while in prison and won’t have to give any of it to the goldman family pnot even free money can make some people go to the gym phow realestate tv shows determine what buyers look for in a house pwhat eleanor roosevelt and helen gurley brown ate — and what we can learn from it pnote to parents this social network was rated the worst for teenage cyberbullying pif like sean spicer you suddenly quit your job — what should you do next pthis is the deadliest time of your life to put on weight p unfortunate reasons why millennials can’t have nice things or save any money pus giving takeover bids by chinese firms much tougher look pjared kushner discloses dozens of additional assets in revised filing pbitcoin surges as miners avert split for now loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  apricus biosciences inc apriph company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile apricus biosciences inc apriph related topics stocksstock screenerhealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse apriph on philadelphia stock exchange usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description apricus biosciences inc incorporated on october   is a pharmaceutical company which develops pharmaceutical products the company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology the companys drug delivery technology is a permeation enhancer called nexact it has over two product candidates in phase ii development fispemifene for the treatment of symptomatic male secondary hypogonadism and rayva for the treatment of raynauds phenomenon secondary to scleroderma the company has a commercial product vitaros for the treatment of erectile dysfunction ed which is in development in the united states approved in canada and marketed throughout europefispemifenefispemifene is a oncedaily orally administered tissuespecific selective estrogen receptor modulator designed to treat a range of mens health conditions including secondary hypogonadism lower urinary tract symptoms luts and chronic prostatitis in men fispemifene acts in secondary hypogonadism by inhibiting the negative feedback of testosterone production through an estrogenblocking effect at the level of pituitary resulting in increased testosterone production in the testes which in turn restores circulating testosterone levels to within but not beyond the normal range fispemifene has also shown other positive tissue effects in animal studies such as preserving bone density antiproliferative activity in prostate and breast cancer the company is conducting a randomized doubleblind phase iib clinical trial in symptomatic secondary hypogonadismrayvarayva is the companys product candidate for the treatment of raynauds phenomenon associated with scleroderma systemic sclerosis rayva product combines alprostadil which dilates blood vessels with its permeation enhancer nexact and is applied as an ondemand topical cream to affected extremities raynauds phenomenon is characterized by constriction of the blood vessels in response to cold or stress of the hands and feet resulting in reduced blood flow and the sensation of pain which can be severe rayva utilizes its nexact technology combining alprostadil and nexact in an ondemand topical application to the affected areas the company has completed a phase iia clinical trial of rayva for the treatment of raynauds phenomenon secondary to sclerodermavitarosvitaros the companys product for the treatment of ed is a topicallyapplied cream formulation of alprostadil a vasodilator and nexact which directly increases blood flow to the penis causing an erection vitaros is manufactured by therapex a division of ezem canada inc a subsidiary of bracco spa in italy therapex and by groupe parima inc vitaros is marketed in the netherlands germany the united kingdom ireland italy france belgium luxembourg spain sweden austria denmark finland iceland norway portugal and romaniathe company competes with pfizer glaxosmithkline endo pharmaceuticals inc the menarini group meda futura medical inc abbott labs and eli lilly » full overview of apriph company address apricus biosciences inc  el camino real ste san diego   ca    p f  company web links home page officers  directors name compensation kleanthis xanthopoulos  richard pascoe  brian dorsey  paul maier  rusty ray  » more officers  directors apricus biosciences inc news briefapricus biosciences reports initiation of vitaros drugdevice human factors study may   correctedbriefapricus biosciences sees offering of up to  mln units april  apr   briefapricus biosciences files for offering of up to  mln of units apr   briefapricus biosciences files for offering of up to  mln shares  sec filing mar   briefapricus biosciences announces sale of exus vitaros assets rights to ferring pharmaceuticals mar   » more apriph news related topics stocksstock screenerhealthcarepharmaceuticals apri stock price  apricus biosciences inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers ctas  cof  etfc  syf  hp  isrg  hban  chk  latest newsall times eastern p updated trump says he has ‘complete power to pardon’ p lawmakers reach deal on russia sanctions bill reports p alphabet earnings a  billion hit for google potential youtube results for investors p updated you can date someone who looks just like donald trump with this new online service p updated want to buy happiness splurge on these  things p this is what people really buy when they emotionally overspend hint it’s not designer clothes p updated john mccain is a war hero — but think twice before saying he’s ‘battling’ cancer p updated the dark side of cruises p updated i want to buy my brothers out of our family home — but they want me to pay future sales fees p updated oj simpson made over  while in prison and won’t have to give any of it to the goldman family to be replaced home investing quotes stocks united states apri overview compare quotes stock screener earnings calendar sectors nasdaq apri us nasdaq join td ameritrade find a broker apricus biosciences inc watchlist createaprialert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones  cheapest stocks in the nasdaq’s hottest sector feb   at  am et by philip van doorn  stocks that are pushing the nasdaq to  feb   at  pm et by philip van doorn apricus biosciences up  in premarket oct   at  am et by steve gelsi thursday’s biggest gaining and declining stocks sep   at  pm et by marketwatch apricus prices stock offering at  discount feb   at  am et drug stocks mixed regeneron rallies nov   at  pm et by val brickates kennedy apricus rockets on liver cancer drug update nov   at  am et by val brickates kennedy updates advisories and surprises sep   at  pm et by marketwatch apricus biosciences drops  after unit offering sep   at  am et by steve gelsi stocks to watch mcdonalds apricus dynavax jun   at  am et on the wall street journal recent news other news press releases apricus biosciences apri ceo richard pascoe on q  results  earnings call transcript apricus biosciences apri ceo richard pascoe on q  results  earnings call transcript may   at  pm et on seeking alpha q apricus biosciences inc q apricus biosciences inc may   at  pm et on edgar online  edg  q k charles brandes invests in health care in st quarter charles brandes invests in health care in st quarter may   at  am et on gurufocuscom esterline technologies corporation esl leads  notable investor filings esterline technologies corporation esl leads  notable investor filings may   at  pm et on investorplacecom apricus prices equity offering at unit shares off  premarket apr   at  am et on seeking alpha apricus biosciences apri ceo richard pascoe on q  results  earnings call transcript mar   at  pm et on seeking alpha k apricus biosciences inc mar   at  pm et on edgar online  edg  q k  stocks to watch on thursday snap inc snap apricus biosciences inc apri and elf beauty inc elf mar   at  am et on investorplacecom apricus completes sale of exus rights to vitaros to ferring mar   at  pm et on seeking alpha apricus apri stock gains on vitaros approval in mexico jan   at  am et on zackscom apricus biosciences inc apri stock scores win on vitaros approval jan   at  pm et on investorplacecom apricus bios topical ed cream okd in mexico shares gallop  jan   at  am et on seeking alpha apricus launches vitaros in lebanon for erectile dysfunction dec   at  am et on zackscom zackscom featured highlights baxter international mam software group advanced energy industries apricus biosciences and copart dec   at  am et on zackscom apricus apri presents at ld micro main event dec   at  pm et on seeking alpha  efficient stocks to buy for superlative returns dec   at  am et on zackscom apricus bio faces delisting from nasdaq dec   at  am et on seeking alpha apricus biosciences aims to resubmit vitaros nda in  nov   at  am et on zackscom apricus bio expects to resubmit vitaros nda next year now considered drugdevice combination shares down  premarket nov   at  am et on seeking alpha apricus biosciences inc  q  results  earnings call slides nov   at  pm et on seeking alpha daily technical summary reports on drug makers stocks  apricus biosciences durect sucampo pharma and sciclone pharma daily technical summary reports on drug makers stocks  apricus biosciences durect sucampo pharma and sciclone pharma jun   at  am et on pr newswire  prf technical reports on drug makers stocks  synergy pharma novo nordisk apricus biosciences and sucampo pharma technical reports on drug makers stocks  synergy pharma novo nordisk apricus biosciences and sucampo pharma may   at  am et on pr newswire  prf apricus biosciences provides corporate update and first quarter  financial results apricus biosciences provides corporate update and first quarter  financial results may   at  pm et on globenewswire apricus biosciences provides corporate update and first quarter  financial results apricus biosciences provides corporate update and first quarter  financial results may   at  pm et on globe newswire investor network apricus biosciences inc to host earnings call investor network apricus biosciences inc to host earnings call may   at  pm et on accesswire apricus biosciences announces the initiation of vitaros drugdevice human factors study apricus biosciences announces the initiation of vitaros drugdevice human factors study may   at  am et on globe newswire apricus biosciences announces the initiation of vitaros drugdevice human factors study apricus biosciences announces the initiation of vitaros drugdevice human factors study may   at  am et on globenewswire apricus biosciences announces corporate update and first quarter  financial results conference call apricus biosciences announces corporate update and first quarter  financial results conference call may   at  am et on globenewswire apricus biosciences announces corporate update and first quarter  financial results conference call apricus biosciences announces corporate update and first quarter  financial results conference call may   at  am et on globe newswire apricus biosciences regains compliance with nasdaq continued listing requirements apricus biosciences regains compliance with nasdaq continued listing requirements may   at  pm et on globenewswire apricus biosciences regains compliance with nasdaq continued listing requirements apricus biosciences regains compliance with nasdaq continued listing requirements may   at  pm et on globe newswire apricus biosciences announces pricing of  million public offering apr   at  am et on globe newswire apricus biosciences announces pricing of  million public offering apr   at  am et on globenewswire apricus biosciences and protalix biotherapeutics seeing opposite sides of fda clinical trials apr   at  am et on accesswire drug makers stocks under scanner  synergy pharma novo nordisk apricus biosciences and sucampo pharma apr   at  am et on pr newswire  prf apricus biosciences provides corporate update fourth quarter and full year  financial results mar   at  pm et on globe newswire apricus biosciences provides corporate update fourth quarter and full year  financial results mar   at  pm et on globenewswire apricus biosciences announces corporate update fourth quarter and full year  financial results conference call mar   at  am et on globe newswire apricus biosciences announces corporate update fourth quarter and full year  financial results conference call mar   at  am et on globenewswire apricus biosciences announces sale of exus vitaros assets and rights to ferring pharmaceuticals mar   at  pm et on globenewswire apricus biosciences inc apricus biosciences inc is a pharmaceutical company focus on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology the company products include vitaros and femprox it operates through pharmaceutical segment which designs and develops pharmaceutical products including those with its nexact platform apricus biosciences was founded in  and is headquartered in san diego ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top upgrades downgrades for april   apr   at  am et on benzingacom benzingas top downgrades dec   at  am et on benzingacom partner content trending tickers powered by dvax  bidu  trp  athn  wd  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ptrump says he has ‘complete power to pardon’ plawmakers reach deal on russia sanctions bill reports palphabet earnings a  billion hit for google potential youtube results for investors pyou can date someone who looks just like donald trump with this new online service pwant to buy happiness splurge on these  things pthis is what people really buy when they emotionally overspend hint it’s not designer clothes pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pi want to buy my brothers out of our family home — but they want me to pay future sales fees poj simpson made over  while in prison and won’t have to give any of it to the goldman family pnot even free money can make some people go to the gym phow realestate tv shows determine what buyers look for in a house pwhat eleanor roosevelt and helen gurley brown ate — and what we can learn from it pnote to parents this social network was rated the worst for teenage cyberbullying pif like sean spicer you suddenly quit your job — what should you do next pthis is the deadliest time of your life to put on weight p unfortunate reasons why millennials can’t have nice things or save any money pus giving takeover bids by chinese firms much tougher look pjared kushner discloses dozens of additional assets in revised filing pbitcoin surges as miners avert split for now loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ptrump says he has ‘complete power to pardon’ plawmakers reach deal on russia sanctions bill reports palphabet earnings a  billion hit for google potential youtube results for investors pyou can date someone who looks just like donald trump with this new online service pwant to buy happiness splurge on these  things pthis is what people really buy when they emotionally overspend hint it’s not designer clothes pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pi want to buy my brothers out of our family home — but they want me to pay future sales fees poj simpson made over  while in prison and won’t have to give any of it to the goldman family pnot even free money can make some people go to the gym phow realestate tv shows determine what buyers look for in a house pwhat eleanor roosevelt and helen gurley brown ate — and what we can learn from it pnote to parents this social network was rated the worst for teenage cyberbullying pif like sean spicer you suddenly quit your job — what should you do next pthis is the deadliest time of your life to put on weight p unfortunate reasons why millennials can’t have nice things or save any money pus giving takeover bids by chinese firms much tougher look pjared kushner discloses dozens of additional assets in revised filing pbitcoin surges as miners avert split for now loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ptrump says he has ‘complete power to pardon’ plawmakers reach deal on russia sanctions bill reports palphabet earnings a  billion hit for google potential youtube results for investors pyou can date someone who looks just like donald trump with this new online service pwant to buy happiness splurge on these  things pthis is what people really buy when they emotionally overspend hint it’s not designer clothes pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pi want to buy my brothers out of our family home — but they want me to pay future sales fees poj simpson made over  while in prison and won’t have to give any of it to the goldman family pnot even free money can make some people go to the gym phow realestate tv shows determine what buyers look for in a house pwhat eleanor roosevelt and helen gurley brown ate — and what we can learn from it pnote to parents this social network was rated the worst for teenage cyberbullying pif like sean spicer you suddenly quit your job — what should you do next pthis is the deadliest time of your life to put on weight p unfortunate reasons why millennials can’t have nice things or save any money pus giving takeover bids by chinese firms much tougher look pjared kushner discloses dozens of additional assets in revised filing pbitcoin surges as miners avert split for now loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  apri stock price  apricus biosciences inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers ctas  cof  etfc  syf  hp  isrg  hban  chk  latest newsall times eastern p updated trump says he has ‘complete power to pardon’ p lawmakers reach deal on russia sanctions bill reports p alphabet earnings a  billion hit for google potential youtube results for investors p updated you can date someone who looks just like donald trump with this new online service p updated want to buy happiness splurge on these  things p this is what people really buy when they emotionally overspend hint it’s not designer clothes p updated john mccain is a war hero — but think twice before saying he’s ‘battling’ cancer p updated the dark side of cruises p updated i want to buy my brothers out of our family home — but they want me to pay future sales fees p updated oj simpson made over  while in prison and won’t have to give any of it to the goldman family to be replaced home investing quotes stocks united states apri overview compare quotes stock screener earnings calendar sectors nasdaq apri us nasdaq join td ameritrade find a broker apricus biosciences inc watchlist createaprialert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones  cheapest stocks in the nasdaq’s hottest sector feb   at  am et by philip van doorn  stocks that are pushing the nasdaq to  feb   at  pm et by philip van doorn apricus biosciences up  in premarket oct   at  am et by steve gelsi thursday’s biggest gaining and declining stocks sep   at  pm et by marketwatch apricus prices stock offering at  discount feb   at  am et drug stocks mixed regeneron rallies nov   at  pm et by val brickates kennedy apricus rockets on liver cancer drug update nov   at  am et by val brickates kennedy updates advisories and surprises sep   at  pm et by marketwatch apricus biosciences drops  after unit offering sep   at  am et by steve gelsi stocks to watch mcdonalds apricus dynavax jun   at  am et on the wall street journal recent news other news press releases apricus biosciences apri ceo richard pascoe on q  results  earnings call transcript apricus biosciences apri ceo richard pascoe on q  results  earnings call transcript may   at  pm et on seeking alpha q apricus biosciences inc q apricus biosciences inc may   at  pm et on edgar online  edg  q k charles brandes invests in health care in st quarter charles brandes invests in health care in st quarter may   at  am et on gurufocuscom esterline technologies corporation esl leads  notable investor filings esterline technologies corporation esl leads  notable investor filings may   at  pm et on investorplacecom apricus prices equity offering at unit shares off  premarket apr   at  am et on seeking alpha apricus biosciences apri ceo richard pascoe on q  results  earnings call transcript mar   at  pm et on seeking alpha k apricus biosciences inc mar   at  pm et on edgar online  edg  q k  stocks to watch on thursday snap inc snap apricus biosciences inc apri and elf beauty inc elf mar   at  am et on investorplacecom apricus completes sale of exus rights to vitaros to ferring mar   at  pm et on seeking alpha apricus apri stock gains on vitaros approval in mexico jan   at  am et on zackscom apricus biosciences inc apri stock scores win on vitaros approval jan   at  pm et on investorplacecom apricus bios topical ed cream okd in mexico shares gallop  jan   at  am et on seeking alpha apricus launches vitaros in lebanon for erectile dysfunction dec   at  am et on zackscom zackscom featured highlights baxter international mam software group advanced energy industries apricus biosciences and copart dec   at  am et on zackscom apricus apri presents at ld micro main event dec   at  pm et on seeking alpha  efficient stocks to buy for superlative returns dec   at  am et on zackscom apricus bio faces delisting from nasdaq dec   at  am et on seeking alpha apricus biosciences aims to resubmit vitaros nda in  nov   at  am et on zackscom apricus bio expects to resubmit vitaros nda next year now considered drugdevice combination shares down  premarket nov   at  am et on seeking alpha apricus biosciences inc  q  results  earnings call slides nov   at  pm et on seeking alpha daily technical summary reports on drug makers stocks  apricus biosciences durect sucampo pharma and sciclone pharma daily technical summary reports on drug makers stocks  apricus biosciences durect sucampo pharma and sciclone pharma jun   at  am et on pr newswire  prf technical reports on drug makers stocks  synergy pharma novo nordisk apricus biosciences and sucampo pharma technical reports on drug makers stocks  synergy pharma novo nordisk apricus biosciences and sucampo pharma may   at  am et on pr newswire  prf apricus biosciences provides corporate update and first quarter  financial results apricus biosciences provides corporate update and first quarter  financial results may   at  pm et on globenewswire apricus biosciences provides corporate update and first quarter  financial results apricus biosciences provides corporate update and first quarter  financial results may   at  pm et on globe newswire investor network apricus biosciences inc to host earnings call investor network apricus biosciences inc to host earnings call may   at  pm et on accesswire apricus biosciences announces the initiation of vitaros drugdevice human factors study apricus biosciences announces the initiation of vitaros drugdevice human factors study may   at  am et on globe newswire apricus biosciences announces the initiation of vitaros drugdevice human factors study apricus biosciences announces the initiation of vitaros drugdevice human factors study may   at  am et on globenewswire apricus biosciences announces corporate update and first quarter  financial results conference call apricus biosciences announces corporate update and first quarter  financial results conference call may   at  am et on globenewswire apricus biosciences announces corporate update and first quarter  financial results conference call apricus biosciences announces corporate update and first quarter  financial results conference call may   at  am et on globe newswire apricus biosciences regains compliance with nasdaq continued listing requirements apricus biosciences regains compliance with nasdaq continued listing requirements may   at  pm et on globenewswire apricus biosciences regains compliance with nasdaq continued listing requirements apricus biosciences regains compliance with nasdaq continued listing requirements may   at  pm et on globe newswire apricus biosciences announces pricing of  million public offering apr   at  am et on globe newswire apricus biosciences announces pricing of  million public offering apr   at  am et on globenewswire apricus biosciences and protalix biotherapeutics seeing opposite sides of fda clinical trials apr   at  am et on accesswire drug makers stocks under scanner  synergy pharma novo nordisk apricus biosciences and sucampo pharma apr   at  am et on pr newswire  prf apricus biosciences provides corporate update fourth quarter and full year  financial results mar   at  pm et on globe newswire apricus biosciences provides corporate update fourth quarter and full year  financial results mar   at  pm et on globenewswire apricus biosciences announces corporate update fourth quarter and full year  financial results conference call mar   at  am et on globe newswire apricus biosciences announces corporate update fourth quarter and full year  financial results conference call mar   at  am et on globenewswire apricus biosciences announces sale of exus vitaros assets and rights to ferring pharmaceuticals mar   at  pm et on globenewswire apricus biosciences inc apricus biosciences inc is a pharmaceutical company focus on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology the company products include vitaros and femprox it operates through pharmaceutical segment which designs and develops pharmaceutical products including those with its nexact platform apricus biosciences was founded in  and is headquartered in san diego ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top upgrades downgrades for april   apr   at  am et on benzingacom benzingas top downgrades dec   at  am et on benzingacom partner content trending tickers powered by dvax  bidu  trp  athn  wd  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience apricus biosciences inc  apri  stock price today  zacks quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  drugs zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for apri all zacks’ analyst reports premium research for apri zacks rank hold  zacks industry rank top  out of  zacks sector rank bottom   out of  style scores f value  b growth  d momentum  d vgm earnings esp  research report for apri snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find earnings surprises by focusing on the most recent analyst revisions this is done because generally speaking if an analyst reevaluates their earnings estimate right before an earnings release it means that they have fresh information which could potentially be more accurate than what analysts thought about a company two or three months ago the crux of this approach is comparing the most accurate estimate to the zacks consensus estimate although the zacks rank is also an important feature of the esp metric combining these two can help investors find stocks that are ready to beat the consensus at their next report and hopefully surge higher in price too in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time and best of all by using these parameters investors have seen  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank apricus biosciences inc apri aerie pharmaceuticals inc aeri chemocentryx inc ccxi consort medical plc sponsored adr csrmy ionis pharmaceuticals inc ions recordati industria chimica e farmaceutica spa rcdtf summit therapeutics plc smmt see all medical  drugs peers zacks news for apri apricus apri stock gains on vitaros approval in mexico am est zacks apricus launches vitaros in lebanon for erectile dysfunction am est zacks apri what are zacks experts saying now zacks private portfolio services  efficient stocks to buy for superlative returns am est zacks apricus biosciences aims to resubmit vitaros nda in  am est zacks company summary apricus bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery its proprietary drug delivery technology is called nexact ® backed by revenue generating cro business bioquant inc and its nexmed usa subsidiary apricus bio has leveraged the flexibility of its proven nexact® drug delivery technology to enable multiroute administration of new and improved compounds across numerous therapeutic classes the company is seeking to monetize its existing product pipeline including compounds from preclinical through phase  currently focused on dermatology sexual dysfunction and cancer apricus bio was formerly known as nexmed inc and is headquartered in san diago california microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft apricus biosciences  netfind content results aol search skip over navigation search the web web web content learn about biosimilars  examinebiosimilarscom ad · examinebiosimilarscom find info about how biosimilars are defined by the fda about biosimilars biosimilar labels biosimilar extrapolation biosimilars vs generics biorad pcr reagents  speed up your qpcr by  ad · wwwbioradcom speed up your qpcr by  faster qpcr with biorad the weed stock rocket  moneymorningcom ad · moneymorningcom​marijuanastocks its a once in a lifetime opportunity for investors get rich from legal weed weed stocks set to soar americas next gold rush apricus biosciences apricus biosciences inc is a san diego based biopharmaceutical company advancing innovative medicines in urology and rheumatology apricus biosciences first product more go to encyclopedia  news  videos  reference source wikipedia results from the wowcom content network apricus biosciences  wowcom wwwwowcomwikiapricusbiosciences history until september   when it formally changed its name apricus biosciences inc nasdaq apri had been operating in the pharmaceutical industry since  apricus biosciences inc apri  aolcom httpswwwaolcomstockquotesnasdaqapricusbiosciencesincapri view the basic apri stock information on aol finance and compare apricusbiosciencesinc against other companies anita h clayton md  huffpost wwwhuffingtonpostcomauthoranitahclaytonmd anita h clayton md interim chair  advisory board feeconsultant fee apricus biosciences inc euthymics forest research institute inc lundbeck  according to science your sex drive is real  huffpost wwwhuffingtonpostcomaccordingtoscienceyourbhtml according to science your sex drive is real  disclosure dr clayton is a consultant to or on the advisory boards of apricus biosciences inc  ddaip  wowcom wwwwowcomwikiddaip ddaip is a permeation enhancer   apricus biosciences reports additional analysis showing that mycova is as effective for the treatment of nail fungus as the  stock price and news  aol finance httpswwwaolcomstockquoteslookupapri you can now search stock quotes from your favorite companies mutual funds and other financial assets here bioscience managers limited  wowcom wwwwowcomchannelbiosciencemanagerslimited includes blogs articles opinion bioscience managers limited  makersstocksapricusbiosciencesdurect  kindredbiosciencesannounces  filgrastim  wowcom wwwwowcomwikifilgrastim apricus biosciences is currently developing and testing a product under the brand name nupen which can deliver filgrastim through the skin to improve post  list of companies headquartered in san diego  wowcom wwwwowcomwikilistofcompaniesheadquarteredinsandiego list of companies headquartered in san diego source  apricus biosciences  neurocrine biosciences nuvasive nupen  wowcom wwwwowcomwikinupen for the apricus biosciences product see filgrastim for the south african cricketer see buster nupen nupen nupen location in troms highest point elevation learn about biosimilars  examinebiosimilarscom ad · examinebiosimilarscom find info about how biosimilars are defined by the fda about biosimilars biosimilar labels biosimilar extrapolation biosimilars vs generics biorad pcr reagents  speed up your qpcr by  ad · wwwbioradcom speed up your qpcr by  faster qpcr with biorad the weed stock rocket  moneymorningcom ad · moneymorningcom​marijuanastocks its a once in a lifetime opportunity for investors get rich from legal weed weed stocks set to soar americas next gold rush searches related toapricus biosciences apricus biosciences stock vitaros where can i buy vitaros apricus biosciences linkedin apricus biosciences message board apricus biosciences san diego is vitaros available anywhere now arcus bioscience next related searches apricus biosciences stock vitaros where can i buy vitaros apricus biosciences linkedin apricus biosciences message board apricus biosciences san diego is vitaros available anywhere now arcus bioscience search the web  aol inc all rights reservedprivacy   terms of use   preferences   contact us   powered by bing™ wowcom  part of the aol search network apricus biosciences  apri apri drug delivery system patient friendly drugs san diego by apricus bio dear shareholders over the past two quarters following the disappointing fispemifene clinical trial results we have sharpened our focus on increasing value through the fostering and expansion of our vitaros® commercial partnerships preparing the vitaros nda resubmission and improving the company’s financial position strategic priorities vitaros® alprostadil continue implementation of the us regulatory approval strategy to address the safety and manufacturing issues raised by the fda in the original vitaros nda submission in november the fda provided clarity on the requirements needed to address the deficiencies in the  complete response letter to include suggested additional analysis of existing clinical and nonclinical data the fda feedback did not indicate that new clinical studies would be required for resubmission but the fda did determine that vitaros is now considered a drugdevice combination the company intends to meet with the office of product quality to confirm the necessary device engineering and compliance requirements for the nda resubmission and then resubmit the vitaros nda in the second half of  an fda approval decision is expected after a six month review period continue to support the company’s exus partners’ efforts to build a global vitaros brand and increase revenue by supporting new commercial launches by the company’s partners and assisting the company’s partners in obtaining additional regulatory approvals in their respective territories continue the company’s efforts to license vitaros in available countries throughout asia to include japan china and india and continue to generate the required data to support delivery device improvements and related regulatory submissions with a priority to support the us nda resubmission of the refrigerated version of vitaros and to deliver a commercially viable refrigerated product in canada rayva™ alprostadil explore orphan drug designation in the us and eu and explore global or regional partnerships prior to initiating the phase b study corporatefinancial reduce operating expenses by approximately  in  and  in  as compared to  operating expenses work with nasdaq to try and regain compliance with the minimum  million market value of listed securities requirement as required for continued listing on the nasdaq capital market under nasdaq listing rule b and grow vitaros revenue seek nondilutive capital and utilize lower cost of capital financial instruments to fund operations with the goal of achieving profitability in  apricus’ development priority is now focused on vitaros both to accelerate commercialization outside of the us and to attempt to bring this novel erectile dysfunction therapy to patients in the us next year with the goal of achieving profitability in  as always thank you for your continued support and interest in apricus biosciences warm regards richard w pascoe search live with vitality ceo messageupdated   click picture to view pipeline  click picture to view nsdq  apri     news releases may   apricus biosciences provides corporate update and first quarter  financial results may   apricus biosciences announces the initiation of vitaros drugdevice human factors study presentations may   apricus biosciences corporate presentation bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one